Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.
Rothenberg ML, et al. Among authors: elfring gl.
Ann Oncol. 2001 Nov;12(11):1631-41. doi: 10.1023/a:1013157727506.
Ann Oncol. 2001.
PMID: 11822765
Free article.
Clinical Trial.